Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
VERA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.79 - $51.61
Previous CloseN/A
Volume142.65K
Average Volume (3M)964.32K
Market Cap
$1.65B
Enterprise Value$1.97B
Total Cash (Recent Filing)$92.65M
Total Debt (Recent Filing)$54.64M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 08, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding63,748,290
10 Day Avg. Volume713,056
30 Day Avg. Volume964,322
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)883.47
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.53
Forecast
1Y Price Target
$67.20Price Target Upside159.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends Vera Therapeutics with an 'Outperform' rating and a target price of $75.00.
EarningsPositive 96-week data from the Phase IIb ORIGIN study showed consistent and sustained reductions in Gd-IgA1 and proteinuria, leading to eGFR stabilization, which is considered a 'functional cure' according to experts.
Financial PerformanceVera Therapeutics reported having $640.9M in cash, which is expected to fund operations through the potential approval and commercial launch of atacicept in IgAN.
Bears Say
Competitive PressureVERA experienced a significant sell-off following competitor Otsuka's announcement about their plans to file for a competing treatment.
Regulatory UncertaintyThere is regulatory risk and uncertainty regarding Otsuka’s strategy for sibeprenlimab, which impacts the competitive landscape.
Stock PerformanceVERA shares are underperforming the biotech group, down significantly following competitor earnings results.
---
Ownership Overview
13.61% Insiders
15.97% Mutual Funds
0.10% Other Institutional Investors
56.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $25.79 and its highest was $51.61 in the past 12 months.
What is Vera Therapeutics’s market cap?
Vera Therapeutics’s market cap is $1.65B.
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.812 by $0.092.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -0.73.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 63,748,290 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.812. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Currently, no hedge funds are holding shares in VERA
---
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.20 (159.36% Upside)
$67.20 (159.36% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 73.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.68%
12-Months-Change
Fundamentals
Return on Equity
-44.83%
Trailing 12-Months
Asset Growth
273.96%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics (VERA) is a biotechnology company focused on developing transformative treatments for serious immunological diseases. With a strong emphasis on research and development, the company's core product pipeline includes innovative therapies aimed at addressing unmet needs in the treatment of kidney diseases and other immune-related conditions.
---
VERA Stock 12 Month Forecast
Average Price Target
$67.20
▲(159.36% Upside)
Technical Analysis
Best Analysts Covering VERA
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+80.33%
reiterated a buy rating last month
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +80.33% per trade.
---